CompanyGraph
HBM Holdings Limited
2142 · HKEX · China
Price data from its 6XY listing on FSX, quoted in EUR
harbourbiomed.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.44B, above the global median of $1.18B
- PositionOperating margin is 54.8%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
11.28BHKD1.44B · vs all stocks (USD)
Trailing P/E
16.34xvs Biotechnology peers
Revenue (TTM)
1.41BHKD179.17M · vs all stocks (USD)
Profit Margin
47.16%vs Biotechnology peers
Beta
1.38xvs all stocks
52-Week Change
-9.94%vs all stocks
Market Capitalization
11.28BHKD1.44B · vs all stocks (USD)
Enterprise Value
88.89BHKD11.33B · vs all stocks (USD)
Trailing P/E
16.34xvs Biotechnology peers
Forward P/E
17.82xvs Biotechnology peers
Price to Sales (TTM)
64.75xvs Biotechnology peers
Price to Book (MRQ)
3.54xvs Biotechnology peers
Enterprise to Revenue
63.24xvs Biotechnology peers
Enterprise to EBITDA
139.79xvs Biotechnology peers
Profit Margin
47.16%vs Biotechnology peers
Operating Margin
54.83%vs Biotechnology peers
Return on Assets (TTM)
10.88%vs Biotechnology peers
Return on Equity (TTM)
23.97%vs Biotechnology peers
Revenue (TTM)
1.41BHKD179.17M · vs all stocks (USD)
Revenue per Share (TTM)
0.2170HKDUpdated Sep 20, 2026Quarterly Revenue Growth
20.90%vs Biotechnology peers
Gross Profit (TTM)
1.33BHKD169.44M · vs all stocks (USD)
Net Income (TTM)
662.92MHKD84.50M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.50%vs Biotechnology peers
Operating Cash Flow (TTM)
41.79MHKD5.33M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
63.65MHKD8.11M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-13.00KUSDFY2025 · Dec 31, 2025Revenue
157.97MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
8.73MUSDFY2025 · Dec 31, 2025Gross Profit
149.24MUSDFY2025 · Dec 31, 2025Operating Income
82.38MUSDvs all stocks (USD)
Pre-tax Income
93.54MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.32MUSDFY2025 · Dec 31, 2025Net Income
92.22MUSDFY2025 · Dec 31, 2025EBIT
95.58MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
94.62MUSDFY2025 · Dec 31, 2025Research & Development
39.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.04MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.1200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
791.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
791.53MSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
-888.00KUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
92.22MUSDFY2025 · Dec 31, 2025Free Cash Flow
88.24MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
226.86MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
93.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.23MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-10.13MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.63MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.97MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-7.49MUSDFY2025 · Dec 31, 2025Net Acquisitions
-49.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-176.20MUSDFY2025 · Dec 31, 2025Sale of Investments
176.20MUSDFY2025 · Dec 31, 2025Other Investing Activity
-176.20MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-180.22MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
46.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-32.55MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-25.08MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
161.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
836.01MSharesUpdated Sep 20, 2026Float Shares
527.69MSharesUpdated Sep 20, 2026% Held by Insiders
16.16%vs all stocks
% Held by Institutions
22.20%vs all stocks
Total Cash (MRQ)
2.82BHKD359.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4350HKDUpdated Sep 20, 2026Total Debt (MRQ)
703.84MHKD89.72M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2147xvs Biotechnology peers
Current Ratio (MRQ)
4.90xvs Biotechnology peers
Book Value per Share (MRQ)
3.97HKDUpdated Sep 20, 2026Total Assets
500.26MUSDvs all stocks (USD)
Total Current Assets
445.86MUSDFY2025 · Dec 31, 2025Total Liabilities
133.14MUSDFY2025 · Dec 31, 2025Total Non-current Assets
54.40MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
46.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
86.21MUSDFY2025 · Dec 31, 2025Cash
225.70MUSDFY2025 · Dec 31, 2025Cash Equivalents
176.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
401.90MUSDFY2025 · Dec 31, 2025Accounts Receivable
5.93MUSDFY2025 · Dec 31, 2025Inventory
6.38MUSDFY2025 · Dec 31, 2025Accounts Payable
9.04MUSDFY2025 · Dec 31, 2025Short-term Debt
58.13MUSDFY2025 · Dec 31, 2025Long-term Debt
23.64MUSDFY2025 · Dec 31, 2025Common Stock (Book)
22.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-617.19MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
367.11MUSDvs all stocks (USD)
Treasury Stock
33.95MUSDFY2025 · Dec 31, 202552-Week Low
9.46HKDUpdated Sep 20, 202652-Week High
17.07HKDUpdated Sep 20, 202652-Week Change
-9.94%vs all stocks
Beta
1.38xvs all stocks
50-Day MA
13.74HKDUpdated Sep 20, 2026200-Day MA
12.70HKDUpdated Sep 20, 2026Avg 10-Day Volume
13.87MSharesUpdated Sep 20, 2026Avg 30-Day Volume
10.13MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.8600HKDUpdated Sep 20, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 54.8%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.55Industry median: -0.24Industry P95: 0.38Peers compared: 193
Profit margin is 47.2%, higher than 95% of its Biotechnology peers (median -32.5%)Significant
Profit margin: 0.47Industry median: -0.32Industry P95: 0.39Peers compared: 193
Return on equity is 24%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 0.24Industry median: -0.24Industry P95: 0.23Peers compared: 193
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 84,502,582.572Operating Cash Flow (USD, TTM): 5,327,541.091
Financial Health
Altman Z-Score 6.56: safe zoneNotable
Altman Z-Score: 6.56
High structural barrier to entryNotable
Barrier to Entry: 25.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.44B, above the global median of $1.18BNotable
Market cap (USD): 1,437,794,433.125Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Rigel Pharmaceuticals, Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Euroseas Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Sk Biopharmaceuticals Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels